프레스티지바이오로직스
Financials
Valuation Metrics
프레스티지바이오로직스's Market Cap is ₩1422B. At end of 2025 it was ₩2360B. Ranked #964 of 2,436 in KR market (top 40%), #465 of 1,649 on KOSDAQ (top 28%), #110 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 47%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 142.21B KRW | KR#964/2,436 Sec#110/234 |
| Revenue | 12.53B KRW | KR#2,254/2,436 Sec#170/234 |
| Net Income | -27.47B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 270.29B KRW | KR#1,071/2,436 Sec#76/234 |
| Net Assets | 135.20B KRW | KR#1,176/2,436 Sec#90/234 |
| Employees | 211 | KR#1,054/2,436 Sec#88/234 |
| Value | ||
| P/B | 1.05x | KR#1,620/2,436 Sec#111/234 |
| P/S | 11.35x | KR#2,299/2,436 Sec#169/234 |
| FCF Yield | -16.55% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -20.32% | KR#2,081/2,436 Sec#163/234 |
| ROA | -10.16% | KR#2,079/2,436 Sec#160/234 |
| Op. Margin | -268.74% | KR#2,353/2,436 Sec#194/234 |
| Revenue Growth | 477.83% | KR#22/2,436 Sec#5/234 |
| Financial Health | ||
| Debt Ratio | 199.91% | KR#1,715/2,436 Sec#192/234 |
| Total Debt | 124.12B KRW | KR#641/2,436 Sec#37/234 |
| FCF | -23.53B KRW | KR#1,940/2,436 Sec#188/234 |
| Cash | 1.58B KRW | KR#2,285/2,436 Sec#219/234 |
| Current Ratio | 0.40x | KR#2,298/2,436 Sec#226/234 |
| Performance | ||
| 1Y Return | -49.68% | KR#1,966/2,436 Sec#173/234 |
| 1M Return | -8.09% | KR#1,589/2,436 Sec#151/234 |
| From 52W High | -53.70% | KR#1,168/2,436 Sec#93/234 |
| 1Y MDD | -64.30% | KR#1,660/2,436 Sec#138/234 |
| Trading | ||
| Volume | 512,748 shares | KR#217/2,436 Sec#13/234 |
| Foreign Own. | 42.00% | KR#51/2,436 Sec#4/234 |
| Per Share | ||
| EPS | -456 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,384 KRW | KR#2,189/2,436 Sec#194/234 |
Company Info
Prestige Biologics, established in 2015 and listed on KOSDAQ in 2021, specializes as a contract manufacturing organization for biopharmaceuticals. The company conducts CDEMO business, providing customized contract manufacturing services for advanced biopharmaceuticals with a 6,000L production facility at its first plant. Its second campus features the ALITA platform, integrating a Smart Factory platform with diverse production methods to enable versatile product manufacturing. Prestige Biologics is headquartered in Cheongju-si, Chungcheongbuk-do.